Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Benzodiazepine

or Research material

or [[:Category:NRIs|Selective norepinephrine reuptake inhibitor (NRI)]]

Use the filters below to narrow your results.

Other values:

None (131) · (none, never marketed) (1) · Dalmane (1) · Doral (1) · Halcion (1) · Lexotan (1) · Librium (1) · Mogadon (1) · O-DSMT (1) · Onfi (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Serax (1) · Strattera (1) · Tranxene (1) · Versed (1) · Xanax (1)

5-HT2A agonist (26) · GABAA positive allosteric modulator (21) · Monoamine releasing agent (9) · CB1/CB2 agonist (7) · Dopamine/norepinephrine reuptake inhibitor (5) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Serotonin/norepinephrine/dopamine releasing agent (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · NMDA antagonist (2) · Prodrug of GHB (2)

Other values:

None (145) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · '"`UNIQ--vote-00000013-QINU`"' (1) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)

None (145) · 0.25 mg (1) · Children ≤70 kg: 0.5 mg/kg/day, titrate to 1.2 mg/kg/day after 3 days. Adults and children >70 kg: 40 mg PO once daily for 3 days, then 80 mg/day, then if needed 100 mg/day after 2-4 weeks (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)

None (145) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · Capsules 10, 18, 25, 40, 60, 80, 100 mg (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)

None (145) · 10 mg/d (1) · 100 mg/day (adult); 1.4 mg/kg/day or 100 mg total (pediatric, whichever lower) (1) · N/A (never approved) (1)

None (145) · intranasal; rectal and IV reported. (1) · Oral (3) · sublingual (1)

None (145) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · ADHD effect emerges over 1-2 weeks (slower than psychostimulants); full effect 4-6 weeks (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (145) · 24 hours (once-daily or split BID dosing) (1) · 6 h (immediate-release); ~11 h (extended-release) (1) · 6–10 h subjective; full pharmacologic effect considerably longer. (1)

None (145) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · ~5 hours in extensive CYP2D6 metabolizers; ~21 hours in CYP2D6 poor metabolizers'"`UNIQ--ref-00000014-QINU`"' (1)

None (145) · 80-90% oral (1) · Not formally characterized in humans. (1) · ~63% (oral; extensive first-pass)'"`UNIQ--ref-00000015-QINU`"' (1)

None (145) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (146) · Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US. '''Not a controlled substance''', the principal clinical selling point versus psychostimulant ADHD options. Carries the antidepressant-class '''Boxed Warning''' for suicidal ideation in pediatric patients'"`UNIQ--ref-00000016-QINU`"' (1)

Showing below up to 156 results in range #1 to #156.

1

2

3

4

5

A

B

C

D

E

F

G

GBL

H

I

Isopropylphenidate

J

L

M

N

O

P

Q

Quazepam

R

RTI-111

S

STS-135

T

U

U-47700

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"